Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications
Recruiting now NCT04053439
Run by Sunnybrook Health Sciences Centre · for 60 and older · All sexes
What this study is about
'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance, which are mutations in bone marrow stem cells that give that population of cells a survival or 'clonal' advantage for growth. This study investigates whether CHIP in lymphoma patients aged 60 years and older is a risk factor for chemotherapy-related complications like low blood counts, infections, cardiac events, hospitalizations, dose delays and dose reductions, and failure to recover normal blood counts after chemotherapy finishes.
Who can join (things the study team will check)
✅ You may be able to join if…
- Diagnosis of a lymphoma (ex: diffuse large B cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, Hodgkin's lymphoma, peripheral T cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic lymphoma, hairy cell leukemia, Waldenstrom's macroglobulinemia, anaplastic large cell lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, and mantle cell lymphoma).
- Commencing first or second-line cytotoxic chemotherapy for lymphoma with or without rituximab [ex: cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), cyclophosphamide, vincristine and prednisone (CVP), Fludarabine, fludarabine cyclophosphamide (FC), Bendamustine, cisplatin, cytarabine, dexamethasone (DHAP), etoposide, cytarabine, cisplatin, prednisone (ESHAP), gemcitabine, cisplatin and dexamethasone (GDP), Cladribine, Cyclophosphamide, Epirubicin, Vincristine, Prednisone (CEOP), dose-adjusted Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH)]
🚫 You may not be able to join if…
- Pre-existing diagnosis of myeloid neoplasm
- Circulating lymphocyte count > 10 x 109/L
- Significant uncontrolled renal or hepatic impairment [>1.5 x upper limit of normal (ULN) bilirubin, >1.5 x ULN Alanine aminotransferase (ALT), >1.5 x ULN creatinine]
- HIV
- Active infection
Where this trial is running
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Who to contact
Prasha Sasitharakumar, MHSc · (416) 480-5000 · prasha.sasitharakumar@sunnybrook.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04053439.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.